Monitor upcoming 10-Q filing for any changes in revenue or cash runway; while these sales are modest relative to market cap and likely part of pre-arranged 10b5-1 plans, the concentration among top leadership warrants attention for follow-on signals.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $23.72entry
- T+1 · 7mo ago +0.89%α +0.63% · $23.93
- T+5 · 7mo ago −0.38%α −2.02% · $23.63
- T+20 · 6mo ago −5.65%α −11.69% · $22.38
- T+60 · 4mo ago +21.88%α +13.74% · $28.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at Bicara Therapeutics, including the CEO, CFO, and President/COO, collectively sold $750K worth of shares in open-market transactions over a 7-day period. These sales coincide with recent option exercises, suggesting planned equity monetization rather than reactive selling.
Key Financial Metrics
Key Facts
- CEO Mazumdar Claire sold $354K of shares, following option exercises totaling over $93K in value.
- CFO Hyep Ivan sold $212K of shares, preceded by derivative exercises worth $34.9K.
- President and COO Cohlhepp Ryan sold $184K of shares on April 15.
- Total insider sales: $750K over 7 days, representing 0.05% of the company's $1.5B market cap.
- All sales were open-market (code S), with no issuer-directed or forced transactions.
Financial Impact
$750,000 in total open-market sales by three C-suite executives
Risk Factors
- Perception of lack of confidence if no formal plan disclosure is provided
- Potential for negative market reaction if similar selling continues in next quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BCAX-1776891240914 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers